XEN 45 Gel Stent Implantation in Open Angle Glaucoma: 5-Year Results of a Prospective Study

被引:5
|
作者
Torbey, Julien [1 ]
Paillard, Archibald [1 ]
Rao, Harsha L. [2 ]
Gillman, Kevin [1 ]
Bravetti, Giorgio E. [1 ]
Mermoud, Andre [1 ]
Mansouri, Kaweh [1 ,3 ,4 ]
机构
[1] Glaucoma Res Ctr, Montchoisi Clin, Swiss Visio Network, Lausanne, Switzerland
[2] Narayana Nethralaya, Hulimavu, Bangalore, India
[3] Univ Colorado, Sch Med, Dept Ophthalmol, Denver, CO USA
[4] Montchoisi Clin, Swiss Visio Glaucoma Res Ctr, Ave Servan 38, CH-1006 Lausanne, Switzerland
关键词
glaucoma; microinvasive glaucoma surgery (MIGS); XEN 45 gel stent; surgery; open angle; anterior segment; INTRAOCULAR-PRESSURE; PHACOEMULSIFICATION; SURGERY;
D O I
10.1097/IJG.0000000000002302
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Pr & eacute;cis: XEN 45 Gel Stent is safe and effective for 3 years. The study results provide useful insight into the outcome of XEN 45 Gel Stent surgery over 5 years in daily clinical practice.Purpose: To evaluate 5-year outcomes of XEN 45 gel stent implantation (XEN) in patients with open angle glaucoma.Methods: This is a prospective, single-center, interventional study. XEN implantation either alone (XEN) or combined with phacoemulsification (Phaco + XEN) was performed on 170 consecutive eyes (126 patients) with uncontrolled intraocular pressure (IOP) or disease progression despite medical treatment. "Complete" surgical success at 60 months was defined as unmedicated IOP <= 15 mm Hg and a relative IOP reduction >= 20% from medicated baseline, while "qualified" success allowed fewer ocular hypotensive medications than at baseline. Other definitions of success with various IOP targets were also analyzed. Secondary outcomes included mean IOP and IOP-lowering medication changes and rates of reoperations.Results: Mean age was 78.1 +/- 9.2 years, and 70.3% were female. Mean medicated IOP decreased from 19.8 +/- 7.7 mm Hg [19.6 +/- 7.1 (XEN) vs. 19.8 +/- 7.0 mm Hg (Phaco+XEN)] at baseline to 12.6 +/- 3.1 mm Hg [12.5 +/- 3.1 (XEN) vs. 12.6 +/- 3.1 (Phaco+XEN)] at 5 years (-37.0%; P < 0.001). Medications decreased from 2.0 +/- 1.3 [2.0 +/- 1.3 (XEN) vs. 2.0 +/- 1.3 (Phaco+XEN)] to 0.8 +/- 1.1 [0.8 +/- 1.1 (XEN) vs. 0.8 +/- 1.1 (Phaco + XEN)] (-60%; P<0.001). Needling was performed in 84 eyes (49%), and 19.4% underwent a secondary surgical intervention. Complete success at 3 years was a strong predictor of success at 5 years (odds ratio: 3.06, P<0.01), while needling was associated with higher rates of failure (odds ratio: 3.6, P<0.01).Conclusions: At 5 years, XEN gel stent implantation was a safe procedure and achieved clinically meaningful IOP and medication reduction. Success at 3 years is a predictor of success at 5 years. Needling correlates with higher failure rates.
引用
收藏
页码:909 / 917
页数:9
相关论文
共 50 条
  • [41] The efficacy of XEN gel stent implantation in glaucoma: a systematic review and meta-analysis
    Yang, Xiang
    Zhao, Yang
    Zhong, Yu
    Duan, Xuanchu
    BMC OPHTHALMOLOGY, 2022, 22 (01)
  • [42] Long-term efficacy and safety of XEN-45 gel stent implantation in patients with normal-tension glaucoma
    Nasyrov, Emil
    Gassel, Caroline J.
    Merle, David A.
    Neubauer, Jonas
    Voykov, Bogomil
    BMC OPHTHALMOLOGY, 2024, 24 (01)
  • [43] A Case of Endocarditis Following Endophthalmitis After XEN45 Gel Stent Implantation
    Wisdorf, Martin
    Kowalski, Radoslaw
    Kiessling, David
    Roessler, Gernot F.
    Widder, Randolf A.
    JOURNAL OF GLAUCOMA, 2021, 30 (08) : E357 - E359
  • [44] XEN Gel Stent Versus Nonpenetrating Deep Sclerectomy in Ocular Hypertension and Open Angle Glaucoma Patients
    Almendral-Gomez, Jaime
    Perucho-Martinez, Susana
    Martin-Giral, Elena
    Fernandez-Escamez, Carlos
    Buenasmananas-Maeso, Miriam
    Monja-Alarcon, Natalia
    Toledano-Fernandez, Nicolas
    JOURNAL OF GLAUCOMA, 2023, 32 (06) : 511 - 519
  • [45] Five-year outcomes of ab interno Xen 45 gel stent implantation
    Ejaz Ansari
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2024, 262 : 1263 - 1269
  • [46] Five-year outcomes of ab interno Xen 45 gel stent implantation
    Ansari, Ejaz
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2024, 262 (04) : 1263 - 1269
  • [47] Complications Following XEN45 Gel Stent and Glaucoma Drainage Device Implantation During Glaucoma Fellowship
    Lentz, P. Connor
    Wagner, Isabella V.
    Draper, Christian
    Ang, Bryan
    Boopathiraj, Nithya
    Miller, Darby
    Dorairaj, Syril
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [48] Outcomes and Baseline Predictors of Failure in Primary Standalone Xen45 Gel Stent versus Trabeculectomy for Glaucoma
    Tan, Jeremy C. K.
    Hashimoto, Yohei
    Gabrielle, Pierre Henry
    Garcher, Catherine Creuzot
    White, Andrew
    Dunn, Hamish
    Walland, Mark
    Wechsler, David
    Arnould, Louis
    Lawlor, Mitchell
    OPHTHALMOLOGY GLAUCOMA, 2024, 7 (06): : 539 - 550
  • [49] Predictability of success and open conjunctival revision rates in the subsequent eye after XEN45 Gel Stent implantation according to lens status
    Kiessling, D.
    Rennings, C.
    Hild, M.
    Lappas, A.
    Dietlein, T. S.
    Roessler, G. F.
    Widder, R. A.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 260 (08) : 2639 - 2647
  • [50] Safety and Efficacy of Ab Interno XEN 45 Gel Stent in Patients with Glaucoma and High Myopia
    Sacchi, Matteo
    Fea, Antonio M.
    Monsellato, Gianluca
    Tagliabue, Elena
    Villani, Edoardo
    Ranno, Stefano
    Nucci, Paolo
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (07)